Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children with Neuroblastoma

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

July 31, 2027

Conditions
Delayed Platelet EngraftmentNeuroblastomaAutologous Hematopoietic Stem Cell Transplantation
Interventions
DRUG

Hetrombopag

Patients enrolled were administered Hetrombopag starting from +4d after transplantation on routine medication of recombinant human thrombopoietin injection (rhTPO). The starting dose of Hetrombopag is 2.5mg or 5mg, oral, once daily (starting at 5mg/d for body weight\>20kg; starting from 2.5mg/d for body weight ≤ 20kg). Adjust the dosage based on platelet count every two weeks, with a maximum dose of 7.5mg per day. Stop the medication after 6 weeks of continuous use or when PLT reaches 100 × 10\^9/L.

Trial Locations (1)

Unknown

RECRUITING

Department of Stem Cell Transplantation, Beijing Children's Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Children's Hospital

OTHER